0001193805-20-001528.txt : 20201209 0001193805-20-001528.hdr.sgml : 20201209 20201209081547 ACCESSION NUMBER: 0001193805-20-001528 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20201208 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201209 DATE AS OF CHANGE: 20201209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 201376977 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 8-K 1 e620124_8k-adma.htm
0001368514 false 0001368514 2020-12-08 2020-12-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 8, 2020

 

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)
     
Delaware 001-36728 56-2590442

(State or other jurisdiction

of incorporation)

(Commission

File Number) 

(IRS Employer

Identification No.)

   
465 State Route 17, Ramsey, New Jersey 07446
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (201) 478-5552

 

 
(Former name or former address, if changed since last report.)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ADMA Nasdaq Global Market

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Overview

 

On December 8, 2020 (the “Amendment Date”), ADMA Biologics, Inc., a Delaware corporation (the “Company”), announced that it entered into Amendment No. 2 (the “Amendment”) to that certain Credit Agreement and Guaranty, dated as of February 11, 2019 and previously amended by Amendment No. 1 dated May 3, 2019 (as amended, the “Credit Agreement”), with ADMA Plasma Biologics, Inc. (“ADMA Plasma Biologics”), ADMA BioCenters Georgia Inc. (“ADMA BioCenters”), ADMA BioManufacturing, LLC (“ADMA BioManufacturing” and together with ADMA Plasma Biologics and ADMA BioCenters, the “Subsidiary Guarantors”) and Perceptive Credit Holdings II, LP (the “Lender”).

 

The Amendment provides for additional senior, secured, delayed-draw term loans in an aggregate principal amount of $15.0 million (the “Fourth Tranche”), which the Company drew-down in full on the Amendment Date, on the same terms as the existing term loans described in the Credit Agreement. Concurrently with the draw-down of the Fourth Tranche, the Company prepaid in full all indebtedness, together with all accrued and unpaid interest and fees, costs and expenses, arising under that certain Subordinated Loan Agreement, dated as of June 6, 2017, by and between Biotest Pharmaceuticals Corporation, ADMA Biomanufacturing and the Company, as amended from time to time (the “Biotest Loan”).

 

The Amendment also extends the scheduled maturity date for the loans under the Credit Agreement to March 1, 2024.

 

The Credit Agreement, together with the Amendment, now provides for a senior secured term loan facility with an aggregate principal amount of up to $100.0 million (collectively, the “Credit Facility”), comprised of (i) an initial term loan made on February 11, 2019 with an outstanding principal amount of $45.0 million, (ii) the second tranche term loan made on May 3, 2019, with an outstanding principal amount of $27.5 million, (iii) the third tranche term loan, made on March 20, 2020, with an outstanding principal amount of $12.5 million and (iv) the Fourth Tranche, as evidenced by the Company’s issuance of a promissory note (the “Note”) in favor of the Lender on the Amendment Date, with an outstanding principal amount of $15.0 million. As amended by the Amendment, the Credit Facility has a maturity date of March 1, 2024, subject to acceleration pursuant to the Credit Agreement, including upon an Event of Default (as defined in the Credit Agreement). Borrowings under the Credit Facility have an interest-only term through the duration of the borrowings until the scheduled maturity date of March 1, 2024.

 

A copy of the press release announcing the Company’s entry into the Amendment is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The foregoing is a summary of the material terms of the Amendment and does not purport to be complete. A copy of the Amendment is attached as Exhibit 10.1 and incorporated by reference herein.

 

Interest Rate

 

As previously disclosed at the time of entry into the Credit Agreement, borrowings under the Credit Agreement bear interest at a rate per annum equal to 7.5% (the “Applicable Margin”) plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the Applicable Margin shall automatically increase by an additional 400 basis points. On the last day of each month during the term of the Credit Facility, the Company will pay accrued interest to the Lender.

 

Warrant

 

As consideration for the Amendment, the Company has issued, on the Amendment Date, a Warrant to Purchase Stock to the Lender (the “Warrant”). The Warrant has an exercise price equal to $1.94, which is equal to the trailing 10-day volume weighted average price (“VWAP”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), on the business day immediately prior to the Amendment Date. The Warrant is exercisable for 2,390,000 shares of Common Stock and has an expiration date of December 8, 2030. The Lender represented to the Company, among other things, that it was an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)), and the Company issued the Warrant in reliance upon an exemption from registration contained in Section 4(2) under the Securities Act. The Warrant and the shares of Common Stock issuable thereunder may not be offered, sold, pledged or otherwise transferred in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act.

 

 

 

Item 1.02 Termination of a Material Definitive Agreement.

 

To the extent applicable, the disclosures of the prepayment of the Biotest Loan in Item 1.01 above are incorporated into this Item 1.02 by reference.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

To the extent applicable, the disclosures of the material terms and conditions of the Credit Facility and the Amendment in Item 1.01 above are incorporated into this Item 2.03 by reference.

 

  Item 9.01 Exhibits.

 

(d) Exhibits

 

Exhibit No. Description

 

4.1 Note, dated December 8, 2020, issued by the Company to Perceptive Credit Holdings II, LP.
10.1 Amendment No. 2 to Credit Agreement and Guaranty, dated December 8, 2020
99.1 Press Release of the Company, dated December 9, 2020

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

December 9, 2020 ADMA Biologics, Inc.
   
   
  By:  /s/ Brian Lenz
    Name:  Brian Lenz
    Title: Executive Vice President and Chief Financial Officer
EX-4.1 2 e620124_ex4-1.htm

 

NOTE

 

U.S. $15,000,000 December 8, 2020

 

FOR VALUE RECEIVED, the undersigned, ADMA Biologics, Inc., a Delaware corporation (the “Borrower”), hereby promises to pay to Perceptive Credit Holdings II, LP (the “Lender”), in immediately available funds, the aggregate principal sum set forth above, or, if less, the aggregate unpaid principal amount of all Loans made by the Lender pursuant to Section 2.01 of the Credit Agreement and Guaranty, dated as of February 11, 2019 (as amended or otherwise modified from time to time, the “Credit Agreement”), among the Borrower, the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto and Perceptive Credit Holdings II, LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”), on the date or dates specified in the Credit Agreement, together with interest on the principal amount of such Loans from time to time outstanding thereunder at the rates, and payable in the manner and on the dates, specified in the Credit Agreement.

 

This Note is a Note issued pursuant to the terms of Section 2.03 of the Credit Agreement, and this Note and the holder hereof are entitled to all the benefits and security provided for thereby or referred to therein, to which Credit Agreement reference is hereby made for a statement thereof. All defined terms used in this Note, except terms otherwise defined herein, shall have the same meaning as in the Credit Agreement.

 

THIS NOTE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION; PROVIDED THAT SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW SHALL APPLY.

 

The Borrower hereby waives demand, presentment, protest or notice of any kind hereunder, other than notices provided for in the Loan Documents. The non-exercise by the holder hereof of any of its rights hereunder in any particular instance shall not constitute a waiver thereof in such particular or any subsequent instance.

 

THIS NOTE MAY NOT BE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE TERMS OF THE CREDIT AGREEMENT.

 

[Signature Page Follows]

 

 

  ADMA BIOLOGICS, INC.
   
  By /s/ Brian Lenz
  Name:   Brian Lenz
  Title: Executive Vice President, Chief Financial Officer and Secretary

 

 

 

[Signature Page to Note]

EX-10.1 3 e620124_ex10-1.htm

 

Execution Version

 

AMENDMENT NO. 2 TO CREDIT AGREEMENT AND GUARANTY

 

This AMENDMENT NO. 2 TO CREDIT AGREEMENT AND GUARANTY, dated as of December 8, 2020 (this “Amendment”), is among ADMA Biologics, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto (the “Lenders”), Perceptive Credit Holdings II, LP, a Delaware limited partnership, as administrative agent (in such capacity, together with its successors and assigns, “Administrative Agent”). Reference is made to the Credit Agreement and Guaranty, dated as of February 11, 2019 (as amended by Amendment No. 1 to Credit Agreement and Guaranty, dated as of May 3, 2019, and as subsequently amended or otherwise modified, the “Credit Agreement”), among the Borrower, the Guarantors party thereto, the Lenders party thereto and the Administrative Agent. Capitalized terms used herein without definition shall have the same meanings as set forth in the Credit Agreement, as amended by this Amendment.

 

RECITALS

 

WHEREAS, the Borrower has requested that the Lenders and the Administrative Agent amend the Credit Agreement in order to, among other things, (i) extend the Maturity Date for the Loans, and (ii) provide an additional tranche of senior, secured, delayed-draw term loans in an aggregate principal amount of $15,000,000; and

 

WHEREAS, subject to the terms and conditions hereof, the Lenders party hereto and the Administrative Agent are willing to agree to such amendments and other modifications set forth herein.

 

NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, the parties hereto agree as follows:

 

SECTION 1.    AMENDMENTS.

 

A.          Each of the following definitions in Section 1.01 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

Borrowing” means, as the context may require, (i) the borrowing of the Initial Loan on the Closing Date, (ii) the borrowing of the Delayed Draw Loan on the Delayed Draw Date, (iii) the borrowing of the Tranche 3 Loan on the Tranche 3 Borrowing Date, or (iv) the borrowing of the Tranche 4 Loan on the Tranche 4 Borrowing Date.

 

Borrowing Date” means, as the context may require, (i) with respect to the Initial Loan, the Closing Date, (ii) with respect to the Delayed Draw Loan, the Delayed Draw Date, (iii) with respect to the Tranche 3 Loan, the Tranche 3 Borrowing Date, and (iv) with respect to the Tranche 4 Loan, the Tranche 4 Borrowing Date.

 

Commitment” means, with respect to each Lender, the obligation of such Lender to make Loans to the Borrower in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender’s name on Schedule 1 under the caption “Commitment”, as such Schedule may be amended from time to time pursuant to an Assignment and Assumption or otherwise. The aggregate Commitment amount (cumulative since the Closing Date) on the Amendment No. 2 Effective Date equals $100,000,000.

 

 

Loan Documents” means, collectively, this Agreement, the Notes, the Security Documents, each Borrower Warrant, the Fee Letter, any Guarantee Assumption Agreement, the Intercompany Subordination Agreement, the Intercreditor Agreement and any other subordination agreement, intercreditor agreement or other present or future document, instrument, agreement, certificate or other amendment, waiver or modification of a Loan Document delivered to the Administrative Agent or any Lender in connection with this Agreement or any of the other Loan Documents, in each case, as amended or otherwise modified.

 

Maturity Date” means the earliest to occur of (x) March 1, 2024 and (y) the acceleration of the Obligations pursuant to Section 11.02.

 

Prepayment Premium” means with respect to any prepayment of any outstanding principal amount of the Loans pursuant to Section 3.03(a) or (b) occurring (i) on or prior to December 31, 2021, an amount equal to five percent (5.0%) of the aggregate outstanding principal amount of the Loans being prepaid; (ii) at any time after December 31, 2021 and on or prior to December 31, 2022, an amount equal to two percent (2.0%) of the aggregate outstanding principal amount of the Loans being prepaid; (iii) at any time after December 31, 2022 and on or prior to December 31, 2023, an amount equal to four percent (4.0%) of the aggregate outstanding principal amount of the Loans being prepaid; and (iv) at any time thereafter and prior to the Maturity Date, an amount equal to five percent (5.0%) of the aggregate outstanding principal amount of the Loans being prepaid.

 

Warrant Obligations” means all Obligations of Borrower arising out of, under or in connection with the Borrower Warrants.

 

B.           The following new definitions are added to Section 1.01 of the Credit Agreement in appropriate alphabetical order:

 

Amendment No. 2” means Amendment No. 2 to Credit Agreement and Guaranty, dated as of December 8, 2020, among the Borrower, the Lenders party thereto and the Administrative Agent.

 

Amendment No. 2 Effective Date” means December 8, 2020.

 

Biotest Indebtedness” means indebtedness arising under that certain Subordinated Loan Agreement, dated as of June 6, 2017, by and between Biotest AG (as assignee of Biotest Pharmaceuticals Corporation), ADMA Biomanufacturing, LLC and the Borrower, as amended from time to time.

 

Borrower Warrants” means, collectively, the Warrant, the Tranche 3 Warrant, the Tranche 4 Warrant, and any other warrants exercisable into Equity Interests of the Borrower delivered pursuant to or in connection with this agreement, and any replacements, substitutions, or similar modifications or amendments thereto.

 

 

Tranche 4 Borrowing Date Certificate” has the meaning set forth in Section 6.04(c).

 

Tranche 4 Borrowing Date” means the Business Day on which the Tranche 4 Loan is made hereunder, which shall be (x) no sooner than the date on which each of the conditions precedent set forth in Section 6.04 shall have been satisfied and (y) no later than December 31, 2020.

 

Tranche 4 Loan” means the term loan made by the Lenders on the Tranche 4 Borrowing Date in an aggregate principal amount not to exceed $15,000,000.

 

Tranche 4 Warrant” means that certain Borrower Warrant, dated as of December 8, 2020 and delivered pursuant to Section 6.04(e), as amended, replaced or otherwise modified pursuant to the terms thereof.

 

C.          Section 2.01 of the Credit Agreement is hereby amended by (1) re-designating clauses (d) and (e) as clauses (e) and (f), respectively, and (2) adding a new clause (d) to read as follows:

 

(c)        On the terms and subject to the conditions of this Agreement, the Lenders agree to make the Tranche 4 Loan to the Borrower in a single Borrowing on the Tranche 4 Borrowing Date, in a principal amount equal to such Lender’s Proportionate Share of $15,000,000; provided that, after the Tranche 4 Borrowing Date, each Lender’s Commitment with respect to the Tranche 4 Loan shall automatically terminate.

 

D.          Section 2.02 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

Borrowing Procedures. The Borrower shall deliver to the Administrative Agent an irrevocable Borrowing Notice (x) for the Borrowing of the Initial Loan, at least three (3) (but not more than five (5)) Business Days prior to the Closing Date and (y) for the Borrowing of any of the Delayed Draw Loan, the Tranche 3 Loan or the Tranche 4 Loan, at least five (5) Business Days prior to the proposed Borrowing Date therefor (which notice, if received by the Administrative Agent on a day that is not a Business Day or after 10:00 A.M. (Eastern time) on a Business Day, shall be deemed to have been delivered on the next Business Day).

 

E.           Section 3.02(c) of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

Interest Payment Dates. Accrued interest on the Loans shall be payable in cash, in arrears, on each Payment Date, and upon the payment or prepayment of the Loans (on the principal amount being so paid or prepaid); provided that interest payable at the Default Rate, or any accrued interest not paid on or before the Maturity Date, shall also be payable from time to time on demand by the Administrative Agent until paid in full in cash.

 

 

F.           Section 6 of the Credit Agreement is hereby amended by adding a new Section 6.04 to read as follows:

 

6.04        Conditions to the Borrowing of the Tranche 4 Loan. The obligation of each Lender to make its Tranche 4 Loan on the Tranche 4 Borrowing Date shall be subject to the (i) prior making of each of the Initial Loan on the Closing Date, the Delayed Draw Loan on the Delayed Draw Date and the Tranche 3 Loan on the Tranche 3 Borrowing Date, (ii) the delivery of a Borrowing Notice as required pursuant to Section 2.02(a), and (iii) the prior or concurrent satisfaction of each of the conditions precedent set forth below in this Section 6.04.

 

(a)        Secretary’s Certificate, Etc. The Administrative Agent shall have received from each Obligor (x) a copy of a good standing certificate, dated a date reasonably close to the Tranche 4 Borrowing Date, for each such Person and (y) a certificate, dated as of the Tranche 4 Borrowing Date, duly executed and delivered by such Person’s secretary or assistant secretary, managing member, general partner or equivalent, as to:

 

(i)        resolutions of each such Person’s Board then in full force and effect authorizing the execution, delivery and performance of each Loan Document to be executed by such Person and the Transactions (or confirming that the resolutions executed on the Tranche 3 Borrowing Date remain in effect);

 

(ii)       the incumbency and signatures of each Responsible Officer authorized to execute and deliver each Loan Document to be executed by such Person (or confirming that the incumbency and signatures executed on the Tranche 3 Borrowing Date remain in effect); and

 

(iii)       the full force and validity of each Organic Document of such Person and copies thereof (or confirming that the Organic Documents certified to as of the Tranche 3 Borrowing Date remain in effect);

 

upon which certificates shall be in form and substance reasonably satisfactory to the Administrative Agent and upon which the Administrative Agent and the Lenders may conclusively rely until they shall have received a further certificate of the secretary, assistant secretary, managing member, general partner or equivalent of any such Person cancelling or amending the prior certificate of such Person.

 

(b)        Information Certificate. The Administrative Agent shall have received a fully completed Information Certificate in form and substance reasonably satisfactory to the Administrative Agent, dated as of the Tranche 4 Borrowing Date, duly executed and delivered by a Responsible Officer of the Borrower. All documents and agreements required to be appended to the Information Certificate, shall be in form and substance reasonably satisfactory to the Administrative Agent and the Lenders, shall have been executed and delivered by the requisite parties and shall be in full force and effect.

 

 

(c)       Tranche 4 Borrowing Date Certificate. The following statements shall be true and correct, and the Administrative Agent shall have received a certificate, dated as of the Tranche 4 Borrowing Date and in form and substance reasonably satisfactory to the Administrative Agent (the “Tranche 4 Borrowing Date Certificate”), duly executed and delivered by a Responsible Officer of the Borrower, certifying that: (i) both immediately before and after giving effect to the Borrowing on the Tranche 4 Borrowing Date, (x) the representations and warranties set forth in each Loan Document that are qualified by materiality, Material Adverse Effect or the like are, in each case, true and correct, (y) the representations and warranties set forth in each Loan Document that are not qualified by materiality, Material Adverse Effect or the like are, in each case, true and correct in all material respects, and (z) no Default has occurred and is continuing, or could reasonably be expected to result from the making of the Loans being advanced, or the consummation of any Transactions contemplated to occur, on the Tranche 4 Borrowing Date, (ii) no Material Adverse Change shall have occurred since December 31, 2018, and (iii) all of the conditions set forth in this Section 6.04 have been satisfied (except to the extent waived in writing by the Administrative Agent). All documents and agreements required to be appended to the Tranche 4 Borrowing Date Certificate, if any, shall be in form and substance reasonably satisfactory to the Administrative Agent, shall have been executed and delivered by the requisite parties, and shall be in full force and effect.

 

(d)       Delivery of Notes. The Administrative Agent shall have received for each Lender a Note evidencing such Lender’s Tranche 4 Loan duly executed and delivered by a Responsible Officer of the Borrower.

 

(e)       Delivery of Tranche 4 Warrant. The Administrative Agent shall have received fully executed counterparts of the Tranche 4 Warrant.

 

(f)       Payoff of Biotest Indebtedness. The Administrative Agent shall have received evidence reasonably satisfactory to it that substantially simultaneously with the Borrowing of the Tranche 4 Loan, the Biotest Indebtedness, together with all accrued and unpaid interest and fees, costs and expenses, shall have been indefeasibly paid in full, and the Administrative Agent shall have received executed payoff letters, in form and substance reasonably satisfactory to the Administrative Agent, evidencing such indefeasible payment in full of the Biotest Indebtedness, all documentation and obligations with respect to the Biotest Indebtedness shall have been permanently terminated or cancelled, and all Liens, if any, securing the Biotest Indebtedness shall have been terminated and released.

 

(g)       Opinions of Counsel. The Administrative Agent shall have received one or more opinions, dated the Tranche 4 Borrowing Date and addressed to the Administrative Agent and the Lenders, from independent legal counsel to the Borrower and the other Obligors, in form and substance reasonably acceptable to the Administrative Agent.

 

(h)       Fees, Expenses, Etc. The Administrative Agent shall have received (i) for the account of each of the Lenders, each of the fees payable pursuant to Section 3.D. of Amendment No. 2 and (ii) for its account and the account of each Lender, all other fees, costs and expenses (including legal fees and expenses of Morrison & Foerster LLP) due and payable pursuant to Section 14.03.

 

 

G.          Schedule 1 to the Credit Agreement is hereby amended and restated in its entirety as Exhibit A hereto.

 

SECTION 2.    ACKNOWLEDGEMENT, AGREEMENT AND CONSENT AND REPRESENTATIONS AND WARRANTIES.

 

A.          Each Obligor confirms and agrees that, notwithstanding the effectiveness of this Amendment, the obligations of such Obligor under each Loan Documents to which such Obligor is a party shall not be impaired and each Loan Document to which such Obligor is a party is, and shall continue to be, in full force and effect and is hereby confirmed and ratified in all respects.

 

B.           Each Obligor hereby acknowledges and agrees that the Guaranteed Obligations will include all Obligations under, and as defined in, the Credit Agreement as amended by this Amendment.

 

C.          Each Subsidiary Guarantor acknowledges and agrees that (i) notwithstanding the conditions to effectiveness set forth in this Amendment, such Subsidiary Guarantor is not required by the terms of the Credit Agreement or any other Loan Document to consent to the amendments to the Credit Agreement effected pursuant to this Amendment and (ii) nothing in the Credit Agreement, this Amendment or any other Loan Document shall be deemed to require the consent of such Subsidiary Guarantor to any future amendments to the Credit Agreement.

 

D.          In order to induce the Administrative Agent and the Lenders to enter into this Amendment, each Obligor represents and warrants to the Administrative Agent and the Lenders that the following statements are true, correct and complete:

 

(i)     such Obligor has full power, authority and legal right to enter into this Amendment and each new Loan Document contemplated hereby and to perform its obligations under this Amendment, the Credit Agreement as amended hereby, each such new Loan Document and each existing Loan Document as amended hereby;

 

(ii)  the transactions contemplated by this Amendment are within such Obligor’s corporate powers and have been duly authorized by all necessary corporate and, if required, by all necessary holders of Equity Interests. This Amendment, the Credit Agreement and each other existing Loan Document as amended hereby, and each new Loan Document entered into and delivered pursuant hereto or thereto has been duly executed and delivered by such Obligor and constitutes a legal, valid and binding obligation of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights and (ii) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law);

 

 

(iii)            none of the transactions contemplated by this Amendment (1) requires any Governmental Approval of, registration or filing with, or any other action by, any Governmental Authority or any other Person, except for such as have been obtained or made and are in full force and effect, (2) will violate (x) any Law, (y) any Organic Document of any Obligor or any of its Subsidiaries or (z) any order of any Governmental Authority,, (3) will violate or result in a default under any Material Agreement binding upon any Obligor or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect or (4) will result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of such Obligor or any of its Subsidiaries; and

 

(iv) both immediately before and after giving effect to this Amendment, (x) the representations and warranties set forth in this Amendment and each other Loan Document (including the Credit Agreement as amended hereby and each new Loan Document entered into in connection herewith) that are qualified by materiality, Material Adverse Effect or the like shall, in each case, be true and correct, (y) the representations and warranties set forth in this Amendment and each other such Loan Document that are not qualified by materiality, Material Adverse Effect or the like shall, in each case, be true and correct in all material respects and (z) no Default shall have then occurred and be continuing, or would result from this Amendment or the transaction contemplated hereby.

 

SECTION 3.    CONDITIONS TO EFFECTIVENESS. This Amendment shall become effective only upon the satisfaction of the following conditions precedent (the date of satisfaction of such conditions being referred to as the “Amendment Effective Date”):

 

A.          The Obligors, the Administrative Agent and the Lenders shall have indicated their consent to this Amendment by the execution and delivery of the signature pages hereto to the Administrative Agent.

 

B.           The Tranche 4 Borrowing Date shall have occurred and all conditions precedent thereto (as set forth in the Credit Agreement, as amended hereby) shall have been satisfied.

 

C.          The Lenders shall have received (i) an officer’s certificate of each Obligor, either confirming that (x) there have been no changes to its Organic Documents since the Amendment No. 1 Effective Date, or if there have been changes to its Organic Documents since such date, certifying as to such changes and providing copies of its Organic Documents as in effect on the Amendment Effective Date, and (y) (1) the representations and warranties set forth in this Amendment and each other Loan Document (including the Credit Agreement both immediately before and after giving effect to this Amendment and each new Loan Document required to be delivered in connection herewith) that are qualified by materiality, Material Adverse Effect or the like are, in each case, true and correct, (2) the representations and warranties set forth in this Amendment and each other such Loan Document (including the Credit Agreement both immediately before and after giving effect to this Amendment and each new Loan Document required to be delivered in connection herewith) that are not qualified by materiality, Material Adverse Effect or the like are, in each case, true and correct in all material respects and (3) no Default has occurred and is continuing, or would result from this Amendment or the transaction contemplated hereby, (ii) copies of resolutions of each Obligor’s Board then in full force and effect authorizing the execution, delivery and performance of this Amendment certified by a Responsible Officer of such Obligor, (iii) a copy of a good standing certificate of each Obligor dated a date reasonably close to the Amendment Effective Date, and (iv) an incumbency certificate from each Obligor.

 

 

D.          The Administrative Agent shall have received (i) for the account of each of the Lenders, a delayed draw fee in the amount equal to (x) the original principal amount of the Tranche 4 Loan made on the Tranche 4 Borrowing Date multiplied by (y) 1.0%, (ii) for the account of the Lenders, an amendment fee in an amount equal to $637,500 and (iii) all other fees, costs and expenses (including legal fees and expenses of Morrison & Foerster LLP) due and payable pursuant to Section 14.03 of the Credit Agreement (as amended hereby).

 

SECTION 4.    MISCELLANEOUS

 

A.          Reference to and Effect on the Loan Documents.

 

(i)       On and after the Amendment Effective Date, each reference in the Credit Agreement or any Loan Document (other than this Amendment) to the “Credit Agreement” shall mean and be a reference to the Credit Agreement as amended by this Amendment.

 

(ii)              Except as expressly amended by this Amendment, all of the representations, warranties, terms, covenants, conditions and other provisions of the Loan Documents shall remain unchanged and shall continue to be, and shall remain, in full force and effect in accordance with their respective terms. The amendments, consents and modifications set forth herein shall be limited precisely as provided for herein to the provisions expressly amended herein or otherwise modified or consented to hereby and shall not be deemed to be an amendment to, waiver of, consent to or modification of any other term or provision of the Credit Agreement or any other Loan Document or of any transaction or further or future action on the part of any Obligor which would require the consent of the Lenders or the Administrative Agent under the Credit Agreement or any other Loan Document.

 

(iii)            The execution, delivery and performance of this Amendment shall not constitute a waiver of any provision of, or operate as a waiver of any right, power or remedy of the Administrative Agent or any Lender under any Loan Document or applicable Law.

 

(iv)             This Amendment shall constitute a Loan Document.

 

B.           Captions. The captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Amendment.

 

C.          Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply.

 

D.          Counterparts. This Amendment may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. Delivery of an executed signature page of this Amendment by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.

 

[Signature Pages Follow]

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above.

 

  BORROWER:
     
  ADMA BIOLOGICS, INC.
     
  By /s/ Brian Lenz
  Name: Brian Lenz
  Title: Executive Vice President, Chief Financial Officer and Secretary
     
     
  SUBSIDIARY GUARANTORS:
     
  ADMA BIOCENTERS GEORGIA INC.
     
  By /s/ Brian Lenz
  Name: Brian Lenz
  Title: Vice President and Chief Financial Officer
     
  ADMA BIOMANUFACTURING, LLC
     
  By /s/ Brian Lenz
  Name: Brian Lenz
  Title: Vice President and Chief Financial Officer
     
  ADMA PLASMA BIOLOGICS, INC.
     
  By /s/ Brian Lenz
  Name: Brian Lenz
  Title: Vice President and Chief Financial Officer

 

 

PERCEPTIVE CREDIT HOLDINGS II, LP, as

Administrative Agent and Lender

 

By Perceptive Credit Opportunities GP, LLC, its

general partner

 

By: /s/ Sandeep Dixit  
       Name: Sandeep Dixit  
  Title:   Chief Credit Officer  
     
By: /s/ Sam Chawla  
  Name: Sam Chawla  
  Title: Portfolio Manager  

 

 

Exhibit A

 

Schedule 1
to Credit Agreement

 

Commitments

 

Lender Commitment Proportionate Share
Perceptive Credit Holdings II, LP $100,000,000 100%
TOTAL $100,000,000 100%
EX-99.1 4 e620124_ex99-1.htm

 

 

ADMA Biologics Enters Into $100 Million Credit Facility Loan Amendment with Perceptive Advisors

 

Increases Size of Facility and Extends Interest-Only Period Enabling ADMA to Reach Profitability Prior to Maturity

 

Demonstrates Perceptive’s Commitment and Long-Term Positive Outlook for ADMA’s Commercial IG Drug Product Portfolio, IP Estate, and Asset Value Supported by Plasma Centers and a Vertically Integrated Plasma Fractionation and Fill/Finish Manufacturing Plant

 

RAMSEY, N.J. and BOCA RATON, FL., – December 9, 2020 – ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an amendment to its existing senior secured term loan with Perceptive Advisors (“Perceptive”), which provides for an additional loan tranche of $15 million, increasing the total size of the credit facility to $100 million. The amended terms for the existing $85 million credit facility additionally provide for, among other things, a two-year extension of the interest only period through the duration of the credit facility now maturing in March 2024, at an unchanged borrowing rate of 11%. The newly issued loan tranche of $15 million from Perceptive was fully drawn and used to pay the remaining obligations under the Biotest AG subordinated note entered into in June of 2017, at a 7% mutually agreed discount with no associated prepayment penalties. This additional loan tranche carries the same terms as the amended senior secured loans. There were no modifications made to the existing revenue covenants of the credit facility with Perceptive.

 

“This upsized loan amendment demonstrates Perceptive’s long-term view for the plasma industry and ADMA’s important role as a reliable producer of plasma-derived biologics,” said Joseph Edelman, Chief Executive Officer and Founder of Perceptive Advisors. “We remain committed to supporting ADMA’s business and unlocking shareholder value that we believe has yet to be realized. We are optimistic that the asset value of manufactured plasma and plasma collection centers will continue to appreciate into the future.”

 

“This amendment to our senior secured term loan, with its increased size and extended maturities, strengthens our long-term capital position and allows us to continue to execute on our strategic priorities, including supply chain enhancement initiatives and plasma center expansion, in addition to generating considerable near-term and ongoing revenue growth,” stated Adam Grossman, President and Chief Executive Officer of ADMA. “Despite ongoing COVID-19 headwinds, we remain on track to achieve our previously provided guidance for topline revenues of $250 million or greater by 2024, and we are confident that we are well-positioned to achieve profitability prior to the new 2024 maturity date of the loan. The continued support from Perceptive, who remains our largest equity holder, is a testament to the shareholder value that we believe will be created as we execute on these corporate objectives and establish ADMA as the only fully integrated American plasma fractionator.”

 

 

 

“Perceptive is pleased to provide additional capital to support ADMA’s near-term revenue and profitability growth strategy,” stated Sam Chawla, Portfolio Manager at Perceptive. “The Company has made significant progress and has met all of our goals and objectives to date. We look forward to seeing ADMA’s continued progress and supporting the Company’s mission and value creating business objectives, focused on improving healthcare options for patients at risk of infectious diseases.”

 

The Perceptive credit amendment has an interest-only term with a maturity date of March 1, 2024. Borrowings under the Perceptive credit agreement bear interest at a rate per annum equal to 7.5% plus the greater of one-month LIBOR and 3.5%. ADMA will also issue a warrant to Perceptive to purchase 2,390,000 shares of the Company’s common stock at the lower of ADMA’s closing share price on the date of the amendment and the 10-day VWAP ahead of closing.

 

The debt financing disclosed in this press release is not all inclusive and, as such, the statements in this press release are qualified in their entirety by reference to the description of the debt financing transaction and corresponding exhibits, which are included in a Current Report on Form 8-K filed concurrently with this press release by ADMA with the Securities and Exchange Commission.

 

About Perceptive Advisors (Perceptive)

 

Founded in 1999, Perceptive Advisors is a leading healthcare focused investment firm with over $8.5 billion of regulatory assets under management as of October 29, 2020. Since inception, Perceptive Advisors has focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare.  For more information about Perceptive, visit www.perceptivelife.com.

 

About ADMA Biologics, Inc. (ADMA)

 

ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

 

 

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements about ADMA’s future results of operations; timing of revenue and profitability; execution of corporate objectives and achievement of goals; realization of shareholder value; and future appreciation of the asset value of manufactured plasma and plasma collection centers. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

 

COMPANY CONTACT:

Skyler Bloom

Director, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabio.com

 

INVESTOR RELATIONS CONTACT:

Sam Martin

Managing Director, Argot Partners | 212-600-1902 | sam@argotpartners.com

 

GRAPHIC 5 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 6 adma-20201208.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 adma-20201208_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 adma-20201208_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 9 e620124_8k-adma_htm.xml IDEA: XBRL DOCUMENT 0001368514 2020-12-08 2020-12-08 iso4217:USD shares iso4217:USD shares 0001368514 false 8-K 2020-12-08 ADMA BIOLOGICS, INC. DE 001-36728 56-2590442 465 State Route 17 Ramsey NJ 07446 (201) 478-5552 false false false false false Common Stock ADMA NASDAQ XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Dec. 08, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 08, 2020
Entity File Number 001-36728
Entity Registrant Name ADMA BIOLOGICS, INC.
Entity Central Index Key 0001368514
Entity Tax Identification Number 56-2590442
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 465 State Route 17
Entity Address, City or Town Ramsey
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07446
City Area Code (201)
Local Phone Number 478-5552
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ADMA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://admabiologics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports e620124_8k-adma.htm adma-20201208.xsd adma-20201208_lab.xml adma-20201208_pre.xml e620124_ex10-1.htm e620124_ex4-1.htm e620124_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "e620124_8k-adma.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "e620124_8k-adma.htm" ] }, "labelLink": { "local": [ "adma-20201208_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "adma-20201208_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "adma-20201208.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ADMA", "nsuri": "http://admabiologics.com/20201208", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "e620124_8k-adma.htm", "contextRef": "From2020-12-08to2020-12-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://admabiologics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "e620124_8k-adma.htm", "contextRef": "From2020-12-08to2020-12-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001193805-20-001528-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193805-20-001528-xbrl.zip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end